If Don's comment about institutional investors now being able to invest in RVX and that drove the share price above $2.20 then, to me, it at least implies some institutional investors were sitting in the wings watching this company. This then suggests to me that with a positive FA and a new partner to fund the balance of BoM and the other trials these same investors may put in more $ or other institutional investors may jump in on the assumption that the interest may increase within BPs or that a successful BoM will be a blockbuster.

Who knows... not me. But both scientific momentum and credibility in apabetalone seem to be growing.

GLTA

Toinv